Genetic clues could sharpen lymphoma diagnosis

NCT ID NCT07181785

Completed Knowledge-focused Sponsor: Andrés José Maria Ferreri Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study examined genetic changes in 555 patients with aggressive B-cell lymphomas, such as diffuse large B-cell lymphoma. Researchers used a technique called FISH to look for specific gene rearrangements. The goal was to see if these genetic markers could help classify tumors more accurately according to the 2017 WHO system, which might eventually guide better treatment decisions for high-risk patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to better classification of aggressive lymphomas, helping doctors choose the most effective treatments for each patient.
What could go wrong: This is a retrospective study, meaning it looks back at past data. It cannot prove that a new classification will improve outcomes, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGGRESSIVE B-CELL LYMPHOMA WITH BLASTOID MORPHOLOGY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aggressive B-cell non-Hodgkin lymphoma diffuse large B-cell lymphoma high grade B-cell lymphoma high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)

Contacts and locations

Show contact details

Locations

IRCCS San Raffaele Hospital

Milan, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.